Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009

Authors: Vernon J Lee, Jonathan Yap, Joshua K Tay, Ian Barr, Qiuhan Gao, Hanley J Ho, Boon Huan Tan, Paul M Kelly, Paul A Tambyah, Anne Kelso, Mark I Chen

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Anti-viral prophylaxis is used to prevent the transmission of influenza. We studied serological confirmation of 2009 Influenza A (H1N1) infections during oseltamivir prophylaxis and after cessation of prophylaxis.

Methods

Between 22 Jun and 16 Jul 09, we performed a cohort study in 3 outbreaks in the Singapore military where post-exposure oseltamivir ring chemoprophylaxis (75 mg daily for 10 days) was administered. The entire cohort was screened by RT-PCR (with HA gene primers) using nasopharyngeal swabs three times a week. Three blood samples were taken for haemagglutination inhibition testing - at the start of outbreak, 2 weeks after completion of 10 day oseltamivir prophylaxis, and 3 weeks after the pandemic's peak in Singapore. Questionnaires were also administered to collect clinical symptoms.

Results

237 personnel were included for analysis. The overall infection rate of 2009 Influenza A (H1N1) during the three outbreaks was 11.4% (27/237). This included 11 index cases and 16 personnel (7.1%) who developed four-fold or higher rise in antibody titres during oseltamivir prophylaxis. Of these 16 personnel, 8 (3.5%) were symptomatic while the remaining 8 personnel (3.5%) were asymptomatic and tested negative on PCR. Post-cessation of prophylaxis, an additional 23 (12.1%) seroconverted. There was no significant difference in mean fold-rise in GMT between those who seroconverted during and post-prophylaxis (11.3 vs 11.7, p = 0.888). No allergic, neuropsychiatric or other severe side-effects were noted.

Conclusions

Post-exposure oseltamivir prophylaxis reduced the rate of infection during outbreaks, and did not substantially increase subsequent infection rates upon cessation. Asymptomatic infections occur during prophylaxis, which may confer protection against future infection. Post-exposure prophylaxis is effective as a measure in mitigating pandemic influenza outbreaks.
Appendix
Available only for authorised users
Literature
1.
go back to reference Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS: Oseltamivir Post Exposure Prophylaxis Investigator Group: Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001, 285: 748-54. 10.1001/jama.285.6.748.CrossRefPubMed Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS: Oseltamivir Post Exposure Prophylaxis Investigator Group: Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001, 285: 748-54. 10.1001/jama.285.6.748.CrossRefPubMed
2.
go back to reference Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, Dutkowski R, Ward P, Carr J: Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004, 189 (3): 440-9. 10.1086/381128.CrossRefPubMed Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, Dutkowski R, Ward P, Carr J: Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004, 189 (3): 440-9. 10.1086/381128.CrossRefPubMed
3.
go back to reference Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG: Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999, 341: 1336-43. 10.1056/NEJM199910283411802.CrossRefPubMed Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG: Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999, 341: 1336-43. 10.1056/NEJM199910283411802.CrossRefPubMed
4.
go back to reference Peters PH, Gravenstein S, Norwood P, De Bock V, Van Couter A, Gibbens M, von Planta TA, Ward P: Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001, 49: 1025-31. 10.1046/j.1532-5415.2001.49204.x.CrossRefPubMed Peters PH, Gravenstein S, Norwood P, De Bock V, Van Couter A, Gibbens M, von Planta TA, Ward P: Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001, 49: 1025-31. 10.1046/j.1532-5415.2001.49204.x.CrossRefPubMed
6.
go back to reference Roy A: How well are we managing the influenza A/H1N1 pandemic in the UK?. BMJ. 2009, 339: b2897-10.1136/bmj.b2799.CrossRef Roy A: How well are we managing the influenza A/H1N1 pandemic in the UK?. BMJ. 2009, 339: b2897-10.1136/bmj.b2799.CrossRef
7.
go back to reference Lee VJ, Chen MI: Modeling the Effectiveness of Neuraminidase Inhibitors in Preventing Critical Staff Absenteeism during Pandemic Influenza. EID. 2007, 13: 449-57. 10.3201/eid1303.060309. Lee VJ, Chen MI: Modeling the Effectiveness of Neuraminidase Inhibitors in Preventing Critical Staff Absenteeism during Pandemic Influenza. EID. 2007, 13: 449-57. 10.3201/eid1303.060309.
8.
go back to reference Nicholson KG, Wood JM, Zambon M: Influenza. Lancet. 2003, 362: 1733-45. 10.1016/S0140-6736(03)14854-4.CrossRefPubMed Nicholson KG, Wood JM, Zambon M: Influenza. Lancet. 2003, 362: 1733-45. 10.1016/S0140-6736(03)14854-4.CrossRefPubMed
11.
go back to reference Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M: Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010, 375: 1100-8. 10.1016/S0140-6736(09)62126-7.CrossRefPubMed Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M: Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010, 375: 1100-8. 10.1016/S0140-6736(09)62126-7.CrossRefPubMed
15.
go back to reference Liu PY, Wang LC, Lin YH, Tsai CA, Shi ZY: Outbreak of influenza A and B among military recruits: evidence from viral culture and polymerase chain reaction. J Microbiol Immunol Infect. 2009, 42: 114-21.PubMed Liu PY, Wang LC, Lin YH, Tsai CA, Shi ZY: Outbreak of influenza A and B among military recruits: evidence from viral culture and polymerase chain reaction. J Microbiol Immunol Infect. 2009, 42: 114-21.PubMed
16.
go back to reference Earhart KC, Beadle C, Miller LK, Pruss MW, Gray GC, Ledbetter EK, Wallace MR: Outbreak of influenza in highly vaccinated crew of U.S. navy ship. Emerg Infect Dis. 2001, 7: 463-5.CrossRefPubMedPubMedCentral Earhart KC, Beadle C, Miller LK, Pruss MW, Gray GC, Ledbetter EK, Wallace MR: Outbreak of influenza in highly vaccinated crew of U.S. navy ship. Emerg Infect Dis. 2001, 7: 463-5.CrossRefPubMedPubMedCentral
17.
go back to reference Lessler J, Reich NG, Cummings DA, New York City Department of Health and Mental Hygiene Swine Influenza Investigation Team, Nair HP, Jordan HT, Thompson N: Outbreak of 2009 pandemic influenza A (H1N1) at a New York City School. N Engl J Med. 2009, 361: 2628-36. 10.1056/NEJMoa0906089.CrossRefPubMed Lessler J, Reich NG, Cummings DA, New York City Department of Health and Mental Hygiene Swine Influenza Investigation Team, Nair HP, Jordan HT, Thompson N: Outbreak of 2009 pandemic influenza A (H1N1) at a New York City School. N Engl J Med. 2009, 361: 2628-36. 10.1056/NEJMoa0906089.CrossRefPubMed
18.
go back to reference Cauchemez S, Donnelly CA, Reed C, Ghani AC, Fraser C, Kent CK, Finelli L, Ferguson NM: Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med. 2009, 361: 2619-27. 10.1056/NEJMoa0905498.CrossRefPubMed Cauchemez S, Donnelly CA, Reed C, Ghani AC, Fraser C, Kent CK, Finelli L, Ferguson NM: Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med. 2009, 361: 2619-27. 10.1056/NEJMoa0905498.CrossRefPubMed
19.
go back to reference Chen MI, Lee VJ, Lim WY, Barr IG, Lin RT, Koh GC, Yap J, Cui L, Cook AR, Laurie K, Tan LW, Tan BH, Loh J, Shaw R, Durrant C, Chow VT, Kelso A, Chia KS, Leo YS: Influenza H1N1 seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA. 2010, 303: 1383-91. 10.1001/jama.2010.404.CrossRefPubMed Chen MI, Lee VJ, Lim WY, Barr IG, Lin RT, Koh GC, Yap J, Cui L, Cook AR, Laurie K, Tan LW, Tan BH, Loh J, Shaw R, Durrant C, Chow VT, Kelso A, Chia KS, Leo YS: Influenza H1N1 seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA. 2010, 303: 1383-91. 10.1001/jama.2010.404.CrossRefPubMed
20.
go back to reference Davies JR, Grilli EA, Smith AJ, Hoskins TW: Prophylactic use of amantadine in a boarding school outbreak of influenza A. J Royal College of General Practitioners. 1988, 38: 346-8. Davies JR, Grilli EA, Smith AJ, Hoskins TW: Prophylactic use of amantadine in a boarding school outbreak of influenza A. J Royal College of General Practitioners. 1988, 38: 346-8.
21.
go back to reference Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, Kerr C: Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002, 186: 1582-88. 10.1086/345722.CrossRefPubMed Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, Kerr C: Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002, 186: 1582-88. 10.1086/345722.CrossRefPubMed
Metadata
Title
Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009
Authors
Vernon J Lee
Jonathan Yap
Joshua K Tay
Ian Barr
Qiuhan Gao
Hanley J Ho
Boon Huan Tan
Paul M Kelly
Paul A Tambyah
Anne Kelso
Mark I Chen
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-164

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine